Literature DB >> 20122957

Characterization of a monoPEG20000-Endostar.

Yue Tong1, Kai Zhong, Hong Tian, Xiangdong Gao, Xiangyang Xu, Xiaojin Yin, Wenbing Yao.   

Abstract

In this study, we investigated the PEG attachment site of mono-PEGylated Endostar, a modified recombinant human endostatin approved in China for lung cancer. N-terminal site-directed mono-PEGylation of Endostar was accomplished using mPEG-propionaldehyde derivatives (Mw=20 kDa) under slightly acidic pH conditions (pH 5.5). One-step cation exchange chromatography was used to purify the mono-PEGylated Endostar. Following tryptic digestion, the peptide fragment containing PEG was separated by SDS-PAGE. Barium iodide staining and Western blotting were used to detect the PEG moiety and the N-terminus of Endostar, respectively. The peptide fragment stained by barium iodide showed a positive response to anti-(His) 6 mAb, demonstrating that PEG was located at the N-terminus of Endostar. LC/MS was applied to verify the occurrence of mono-PEGylation at the N-terminus of Endostar. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20122957     DOI: 10.1016/j.ijbiomac.2010.01.017

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  7 in total

1.  Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model.

Authors:  Rui-Lin Ding; Fang Xie; Yue Hu; Shao-Zhi Fu; Jing-Bo Wu; Juan Fan; Wen-Feng He; Yu He; Ling-Lin Yang; Sheng Lin; Qing-Lian Wen
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

2.  Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers.

Authors:  Weijie Chen; Sanyuan Hu
Journal:  Int J Nanomedicine       Date:  2011-07-22

Review 3.  Matricryptins Network with Matricellular Receptors at the Surface of Endothelial and Tumor Cells.

Authors:  Sylvie Ricard-Blum; Sylvain D Vallet
Journal:  Front Pharmacol       Date:  2016-02-04       Impact factor: 5.810

Review 4.  Endostatin in fibrosis and as a potential candidate of anti-fibrotic therapy.

Authors:  Zequn Zhang; Xi Liu; Zhaolong Shen; Jun Quan; Changwei Lin; Xiaorong Li; Gui Hu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

5.  Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer.

Authors:  Zhi-Quan Qin; Si-Fu Yang; Yun Chen; Chao-Jin Hong; Tong-Wei Zhao; Guo-Rong Yuan; Liu Yang; Liang Gao; Xiao Wang; Li-Qin Lu
Journal:  World J Clin Cases       Date:  2022-02-06       Impact factor: 1.337

6.  Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Show a Largely Reduced Affinity for the Target Antigen.

Authors:  Fabio Selis; Giuseppina Focà; Annamaria Sandomenico; Carla Marra; Concetta Di Mauro; Gloria Saccani Jotti; Silvia Scaramuzza; Annalisa Politano; Riccardo Sanna; Menotti Ruvo; Giancarlo Tonon
Journal:  Int J Mol Sci       Date:  2016-04-01       Impact factor: 5.923

7.  Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog.

Authors:  Shan Wang; Yan Fu; Yongzhang Luo
Journal:  Chin J Cancer       Date:  2016-01-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.